819 related articles for article (PubMed ID: 28777143)
1. Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors.
Hendry S; Salgado R; Gevaert T; Russell PA; John T; Thapa B; Christie M; van de Vijver K; Estrada MV; Gonzalez-Ericsson PI; Sanders M; Solomon B; Solinas C; Van den Eynden GGGM; Allory Y; Preusser M; Hainfellner J; Pruneri G; Vingiani A; Demaria S; Symmans F; Nuciforo P; Comerma L; Thompson EA; Lakhani S; Kim SR; Schnitt S; Colpaert C; Sotiriou C; Scherer SJ; Ignatiadis M; Badve S; Pierce RH; Viale G; Sirtaine N; Penault-Llorca F; Sugie T; Fineberg S; Paik S; Srinivasan A; Richardson A; Wang Y; Chmielik E; Brock J; Johnson DB; Balko J; Wienert S; Bossuyt V; Michiels S; Ternes N; Burchardi N; Luen SJ; Savas P; Klauschen F; Watson PH; Nelson BH; Criscitiello C; O'Toole S; Larsimont D; de Wind R; Curigliano G; André F; Lacroix-Triki M; van de Vijver M; Rojo F; Floris G; Bedri S; Sparano J; Rimm D; Nielsen T; Kos Z; Hewitt S; Singh B; Farshid G; Loibl S; Allison KH; Tung N; Adams S; Willard-Gallo K; Horlings HM; Gandhi L; Moreira A; Hirsch F; Dieci MV; Urbanowicz M; Brcic I; Korski K; Gaire F; Koeppen H; Lo A; Giltnane J; Rebelatto MC; Steele KE; Zha J; Emancipator K; Juco JW; Denkert C; Reis-Filho J; Loi S; Fox SB
Adv Anat Pathol; 2017 Nov; 24(6):311-335. PubMed ID: 28777143
[TBL] [Abstract][Full Text] [Related]
2. Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research.
Hendry S; Salgado R; Gevaert T; Russell PA; John T; Thapa B; Christie M; van de Vijver K; Estrada MV; Gonzalez-Ericsson PI; Sanders M; Solomon B; Solinas C; Van den Eynden GGGM; Allory Y; Preusser M; Hainfellner J; Pruneri G; Vingiani A; Demaria S; Symmans F; Nuciforo P; Comerma L; Thompson EA; Lakhani S; Kim SR; Schnitt S; Colpaert C; Sotiriou C; Scherer SJ; Ignatiadis M; Badve S; Pierce RH; Viale G; Sirtaine N; Penault-Llorca F; Sugie T; Fineberg S; Paik S; Srinivasan A; Richardson A; Wang Y; Chmielik E; Brock J; Johnson DB; Balko J; Wienert S; Bossuyt V; Michiels S; Ternes N; Burchardi N; Luen SJ; Savas P; Klauschen F; Watson PH; Nelson BH; Criscitiello C; O'Toole S; Larsimont D; de Wind R; Curigliano G; André F; Lacroix-Triki M; van de Vijver M; Rojo F; Floris G; Bedri S; Sparano J; Rimm D; Nielsen T; Kos Z; Hewitt S; Singh B; Farshid G; Loibl S; Allison KH; Tung N; Adams S; Willard-Gallo K; Horlings HM; Gandhi L; Moreira A; Hirsch F; Dieci MV; Urbanowicz M; Brcic I; Korski K; Gaire F; Koeppen H; Lo A; Giltnane J; Rebelatto MC; Steele KE; Zha J; Emancipator K; Juco JW; Denkert C; Reis-Filho J; Loi S; Fox SB
Adv Anat Pathol; 2017 Sep; 24(5):235-251. PubMed ID: 28777142
[TBL] [Abstract][Full Text] [Related]
3. TILs in Head and Neck Cancer: Ready for Clinical Implementation and Why (Not)?
De Meulenaere A; Vermassen T; Aspeslagh S; Vandecasteele K; Rottey S; Ferdinande L
Head Neck Pathol; 2017 Sep; 11(3):354-363. PubMed ID: 28032290
[TBL] [Abstract][Full Text] [Related]
4. The role of tumor-infiltrating lymphocytes (TILs) as a predictive biomarker of response to anti-PD1 therapy in patients with metastatic non-small cell lung cancer or metastatic melanoma.
Uryvaev A; Passhak M; Hershkovits D; Sabo E; Bar-Sela G
Med Oncol; 2018 Jan; 35(3):25. PubMed ID: 29388007
[TBL] [Abstract][Full Text] [Related]
5. Overall assessment of tumor-infiltrating lymphocytes in head and neck squamous cell carcinoma: time to take notice.
Almangush A; Leivo I; Mäkitie AA
Acta Otolaryngol; 2020 Mar; 140(3):246-248. PubMed ID: 32022615
[No Abstract] [Full Text] [Related]
6. Tumor-infiltrating lymphocytes in oral cavity squamous cell carcinoma and its association with clinicopathological parameters.
Ahuja S; Khan AA; Zaheer S; Ranga S
Pathol Res Pract; 2023 Nov; 251():154882. PubMed ID: 37898039
[TBL] [Abstract][Full Text] [Related]
7. Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in head and neck cancers.
Uppaluri R; Dunn GP; Lewis JS
Cancer Immun; 2008 Dec; 8():16. PubMed ID: 19053167
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of tumor-infiltrating lymphocytes for patients with completely resected stage IIIA(N2) non-small cell lung cancer.
Feng W; Li Y; Shen L; Cai XW; Zhu ZF; Chang JH; Xiang JQ; Zhang YW; Chen HQ; Fu XL
Oncotarget; 2016 Feb; 7(6):7227-40. PubMed ID: 26811495
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1), CD8+ Tumor-Infiltrating Lymphocytes and p53 in Non-Small Cell Lung Cancer: An Immunohistochemical Study.
Rashed HE; Abdelrahman AE; Abdelgawad M; Balata S; Shabrawy ME
Turk Patoloji Derg; 2017; 1(1):211-222. PubMed ID: 28832075
[TBL] [Abstract][Full Text] [Related]
10. Digitally quantified CD8+ cells: the best candidate marker for an immune cell score in non-small cell lung cancer?
Kilvaer TK; Paulsen EE; Andersen S; Rakaee M; Bremnes RM; Busund LR; Donnem T
Carcinogenesis; 2020 Dec; 41(12):1671-1681. PubMed ID: 33035322
[TBL] [Abstract][Full Text] [Related]
11. Measuring multiple parameters of CD8+ tumor-infiltrating lymphocytes in human cancers by image analysis.
Steele KE; Tan TH; Korn R; Dacosta K; Brown C; Kuziora M; Zimmermann J; Laffin B; Widmaier M; Rognoni L; Cardenes R; Schneider K; Boutrin A; Martin P; Zha J; Wiestler T
J Immunother Cancer; 2018 Mar; 6(1):20. PubMed ID: 29510739
[TBL] [Abstract][Full Text] [Related]
12. Characterization of tumor-associated T-lymphocyte subsets and immune checkpoint molecules in head and neck squamous cell carcinoma.
Lechner A; Schlößer H; Rothschild SI; Thelen M; Reuter S; Zentis P; Shimabukuro-Vornhagen A; Theurich S; Wennhold K; Garcia-Marquez M; Tharun L; Quaas A; Schauss A; Isensee J; Hucho T; Huebbers C; von Bergwelt-Baildon M; Beutner D
Oncotarget; 2017 Jul; 8(27):44418-44433. PubMed ID: 28574843
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of tumor-infiltrating lymphocytes using routine H&E slides predicts patient survival in resected non-small cell lung cancer.
Rakaee M; Kilvaer TK; Dalen SM; Richardsen E; Paulsen EE; Hald SM; Al-Saad S; Andersen S; Donnem T; Bremnes RM; Busund LT
Hum Pathol; 2018 Sep; 79():188-198. PubMed ID: 29885403
[TBL] [Abstract][Full Text] [Related]
14. Reproducibility of PD-L1 immunohistochemistry interpretation across various types of genitourinary and head/neck carcinomas, antibody clones, and tissue types.
Wang C; Hahn E; Slodkowska E; Eskander A; Enepekides D; Higgins K; Vesprini D; Liu SK; Downes MR; Xu B
Hum Pathol; 2018 Dec; 82():131-139. PubMed ID: 30075156
[TBL] [Abstract][Full Text] [Related]
15. Presence of the T-cell activation marker OX-40 on tumor infiltrating lymphocytes and draining lymph node cells from patients with melanoma and head and neck cancers.
Vetto JT; Lum S; Morris A; Sicotte M; Davis J; Lemon M; Weinberg A
Am J Surg; 1997 Sep; 174(3):258-65. PubMed ID: 9324133
[TBL] [Abstract][Full Text] [Related]
16. An immunohistochemical comparison of two TTF-1 monoclonal antibodies in atypical squamous lesions and sarcomatoid carcinoma of the lung, and pleural malignant mesothelioma.
Klebe S; Swalling A; Jonavicius L; Henderson DW
J Clin Pathol; 2016 Feb; 69(2):136-41. PubMed ID: 26281863
[TBL] [Abstract][Full Text] [Related]
17. Digital pathology-aided assessment of tumor-infiltrating T lymphocytes in advanced stage, HPV-negative head and neck tumors.
de Ruiter EJ; de Roest RH; Brakenhoff RH; Leemans CR; de Bree R; Terhaard CHJ; Willems SM
Cancer Immunol Immunother; 2020 Apr; 69(4):581-591. PubMed ID: 31980916
[TBL] [Abstract][Full Text] [Related]
18. Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma.
Rebelatto MC; Midha A; Mistry A; Sabalos C; Schechter N; Li X; Jin X; Steele KE; Robbins PB; Blake-Haskins JA; Walker J
Diagn Pathol; 2016 Oct; 11(1):95. PubMed ID: 27717372
[TBL] [Abstract][Full Text] [Related]
19. Expression of immune response biomarkers (PD‑L1, p16, CD3+ and CD8+ TILs) in recurrent head and neck squamous cell carcinoma within previously irradiated areas.
Pflumio C; Thomas J; Salleron J; Faivre JC; Borel C; Dolivet G; Sastre-Garau X; Geoffrois L
Oncol Rep; 2021 Mar; 45(3):1273-1283. PubMed ID: 33432367
[TBL] [Abstract][Full Text] [Related]
20. Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: a guide to immunohistochemistry implementation and interpretation.
Paver EC; Cooper WA; Colebatch AJ; Ferguson PM; Hill SK; Lum T; Shin JS; O'Toole S; Anderson L; Scolyer RA; Gupta R
Pathology; 2021 Feb; 53(2):141-156. PubMed ID: 33388161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
